Dynavax Technologies Corporation (NASDAQ:DVAX) has a beta value of 1.38 and has seen 2,155,755 shares traded in the last trading session. The company, currently valued at $567.39 Million, closed the last trade at $5.15 per share which meant it gained $0.23 on the day or 4.67% during that session. The DVAX stock price is -141.55% off its 52-week high price of $12.44 and 65.05% above the 52-week low of $1.8. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.34 Million shares traded. The 3-month trading volume is 3.02 Million shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The consensus among analysts is that Dynavax Technologies Corporation (DVAX) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.23.

Dynavax Technologies Corporation (NASDAQ:DVAX) trade information

Sporting 4.67% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jan 12 when the DVAX stock price touched $5.17-0 or saw a rise of 0.39%. Year-to-date, Dynavax Technologies Corporation shares have moved 15.73%, while the 5-day performance has seen it change 12.69%. Over the past 30 days, the shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have changed 3.83%. Short interest in the company has seen 24.41 Million shares shorted with days to cover at 8.08.

Wall Street analysts have a consensus price target for the stock at $16, which means that the shares’ value could jump 210.68% from current levels. The projected low price target is $14 while the price target rests at a high of $20. In that case, then, we find that the current price level is +288.35% off the targeted high while a plunge would see the stock lose 171.84% from current levels.

Dynavax Technologies Corporation (DVAX) estimates and forecasts

Figures show that Dynavax Technologies Corporation shares have underperformed across the wider relevant industry. The company’s shares have lost -43.96% over the past 6 months. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 47.7% and -33.3% for the next quarter. Revenue growth from the last financial year stood is estimated to be +13.7%.

3 analysts offering their estimates for the company have set an average revenue estimate of $13.06 Million for the current quarter. 3 have an estimated revenue figure of $24.78 Million for the next quarter concluding in March 01, 2021. Year-ago sales stood $10.57 Million and $11.36 Million respectively for this quarter and the next, and analysts expect sales will grow by 23.6% for the current quarter and 118.1% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +8.9% over the past 5 years. Earnings growth for 2021 is a modest +15.1%.

Dynavax Technologies Corporation (NASDAQ:DVAX)’s Major holders

Insiders own 0.76% of the company shares, while shares held by institutions stand at 80.86% with a share float percentage of 81.48%. Investors are also buoyed by the number of investors in a company, with Dynavax Technologies Corporation having a total of 213 institutions that hold shares in the company. The top two institutional holders are State Street Corporation with over 11.6 Million shares worth more than $50.13 Million. As of September 29, 2020, State Street Corporation held 10.53% of shares outstanding.

The other major institutional holder is Federated Hermes, Inc., with the holding of over 10.95 Million shares as of September 29, 2020. The firm’s total holdings are worth over $47.29 Million and represent 9.94% of shares outstanding.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Federated Hermes Kaufmann Fund. As of December 30, 2020, the former fund manager holds about 8.05% shares in the company for having 8873658 shares of worth $39.49 Million while later fund manager owns 5.95 Million shares of worth $22.19 Million as of October 30, 2020, which makes it owner of about 5.4% of company’s outstanding stock.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on..

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
.

Sponsored


Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

LEAVE A REPLY

Please enter your comment!
Please enter your name here